TrialAnnals of hematology2021

Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.

Armando Santoro et al.PubMed ↗Publisher ↗

No numbers read from the abstract.